₹986.10
−2.81%NSE close, 16 Nov 2026
+4.00%
Strides Pharma Science is a small cap company in the Healthcare sector, listed on NSE under the symbol STAR. At ₹986.10 a share, the market values the whole company at ₹9,089 crore.
In FY26, it reported sales of ₹4,859 crore and a net profit of ₹556 crore, an operating margin of 19.0%. Over the last three years, sales grew 9.6% a year.
The market values the company at 14.7 times its profit over the last twelve months and 2.66 times its book value; its return on equity is 18.1% and its borrowings are 0.54 times its equity.
Promoters hold 29.00% of the shares, and have pledged 33.8% of their holding. Foreign institutions hold 27.98%, and domestic institutions, mutual funds among them, 15.51%.
Over the past year the share price has risen 2.8%, and it is 21.8% below its 52-week high.
Companies of a similar size in the same sector include Park Medi World, Viyash Scientific, Yatharth Hospital & Trauma Care Services and Blue Jet Healthcare.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Strides Pharma Science | ₹986.10 | ₹9,089 cr | 14.7 | 18.1% | +17.10% | +2.78% |
| Park Medi World | ₹245.03 | ₹10,584 cr | 41.3 | 11.9% | n/a | n/a |
| Viyash Scientific | ₹236.38 | ₹10,439 cr | 44.9 | 7.3% | +133.00% | +9.21% |
| Yatharth Hospital & Trauma Care Services | ₹1,069.05 | ₹10,301 cr | 54.9 | 10.0% | +54.40% | +34.65% |
| Blue Jet Healthcare | ₹512.95 | ₹9,709 cr | 34.0 | 12.4% |
Transcript of Earnings Call to discuss the unaudited financial results for the quarter and half year ended September 30, 2026
Link of Recording
Appointment of Biren Gabhawala as Non- Executive Independent Director of the company w.e.f. November 01, 2026.
Allotment of 7500 Shares.
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 1,038 | 1,084 | 1,088 | 1,201 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 | 1,430 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 844 | 854 | 871 | 965 | 943 | 973 | 902 | 989 | 959 | 1,084 | 1,036 | 1,179 |
| Operating profit | 194 | 230 | 217 | 236 | 210 | 218 | 218 | 232 | 236 | 240 | 230 | 251 |
| Operating margin | 18.7% | 21.2% | 20.0% | 19.6% | 18.2% | 18.3% | 19.5% | 19.0% | 19.8% | 18.1% | 18.2% | 17.5% |
| Other income | 8.8 | −13.6 | 12.7 | 28.4 | 5.6 | 12.0 | 8.6 | 27.1 | 107 | 8.1 | 4.9 | 4.1 |
| Interest | 79.3 | 80.2 | 80.4 | 82.2 | 52.2 | 50.3 | 47.5 | 46.1 | 43.4 | 41.6 | 40.6 | 46.5 |
| Depreciation | 51.2 | 49.8 | 48.6 | 50.5 | 48.4 | 48.9 | 48.9 | 49.6 | 50.6 | 53.3 | 56.4 | 57.2 |
| Profit before tax | 62.0 | 78.2 | 97.0 | 128 | 113 | 103 | 122 | 154 | 246 | 147 | 201 | 150 |
| Tax | 10.1 | 19.3 | 16.9 | 21.2 | 23.8 | 20.8 | 16.5 | 21.6 | 37.4 | 18.8 | 34.1 | 16.3 |
| Net profit | 49.7 | 18.2 | 70.2 | 93.2 | 88.0 | 82.2 | 99.6 | 128 | 202 | 127 | 157 | 131 |
| EPS (₹) | 5.43 | 1.98 | 7.64 | 10.14 | 9.56 | 8.92 | 10.81 | 13.84 | 21.93 | 13.77 | 17.02 | 14.19 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,012 | 2,752 | 3,316 | 3,070 | 3,688 | 4,051 | 4,565 | 4,859 |
| Expenses | 2,557 | 2,236 | 2,681 | 3,090 | 3,258 | 3,308 | 3,763 | 3,933 |
| Operating profit | 455 | 516 | 635 | −20.1 | 430 | 743 | 803 | 925 |
| Operating margin | 15.1% | 18.7% | 19.1% | -0.7% | 11.7% | 18.3% | 17.6% | 19.0% |
| Other income | 45.4 | 53.1 | 51.4 | 132 | 90.3 | 39.7 | 58.7 | 151 |
| Interest | 205 | 156 | 150 | 177 | 261 | 314 | 249 | 179 |
| Depreciation | 172 | 174 | 206 | 233 | 243 | 221 | 192 | 202 |
| Profit before tax | 120 | 162 | 373 | −542 | −0.9 | 58.8 | 485 | 668 |
| Tax | 13.1 | 11.3 | 31.7 | −178 | −55.3 | 31.6 | 77.5 | 94.2 |
| Net profit | 325 | 36.4 | 268 | −460 | −203 | −70.6 | 3,593 | 556 |
| EPS (₹) | 36.25 | 4.06 | 29.96 | -51.28 | -22.51 | -7.92 | 390.54 | 60.34 |
₹ crore, at each year's end and the latest half year.
| Line | FY23 | FY24 | FY25 | FY26 | Sep 2026 |
|---|---|---|---|---|---|
| Shareholders’ equity | 2,212 | 2,126 | 2,552 | 3,108 | 3,416 |
| Borrowings | 2,774 | 2,415 | 1,796 | 1,669 | 1,847 |
| Total liabilities | 4,466 | 3,768 | 3,462 | 3,778 | 4,018 |
| Fixed assets | 1,324 | 879 | 881 | 992 | 958 |
| Investments | 53.0 | 7.6 | 329 | 279 | 288 |
| Cash and equivalents | 304 | 161 | 113 | 189 | 137 |
| Total assets | 6,638 | 5,840 | 6,049 | 6,927 | 7,489 |
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | −258 | 684 | 703 | 107 |
| From investing | −119 | −89.7 | −173 | −182 |
| From financing | 421 | −643 | −453 | 25.2 |
| Spent on fixed assets | −143 | −243 | −423 | −266 |
| Free cash flow | −401 | 442 | 280 | −160 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | 10.8% | 1.3% | 8.1% | -15.0% | -5.5% | -1.7% | 78.7% | 11.4% |
| Operating margin | 15.1% | 18.7% | 19.1% | -0.7% | 11.7% | 18.3% | 17.6% | 19.0% |
| Return on equity | – | – | – | – | -9.2% | -3.3% | 140.8% | 17.9% |
| Return on capital employed | – | – | – | – | 5.2% | 8.2% | 16.9% | 17.7% |
| Return on assets | – | – | – | – | -3.1% | -1.2% | 59.4% | 8.0% |
| Debt to equity | – | – | – | – | 1.25 | 1.14 | 0.70 | 0.54 |
| Interest coverage | 1.60 | 2.00 | 3.50 | -2.10 | 1.00 | 1.20 | 2.90 | 4.70 |
| Debt to assets | – | – | – | – | 0.42 | 0.41 | 0.30 | 0.24 |
| Current ratio | – | – | – | – | 1.05 | 1.03 | 1.20 | 1.25 |
| Quick ratio | – | – | – | – | 0.67 | 0.64 | 0.70 | 0.68 |
| Cash ratio | – | – | – | – | 0.10 | 0.06 | 0.04 | 0.07 |
| Asset turnover | – | – | – | – | 0.56 | 0.69 | 0.75 | 0.70 |
| Fixed asset turnover | – | – | – | – | 2.79 | 4.61 | 5.18 | 4.90 |
| Inventory turnover | – | – | – | – | – | 1.50 | 1.50 | 1.20 |
| Receivables turnover | – | – | – | – | 2.80 | 3.50 | 3.80 | 3.80 |
| Gross margin | – | – | – | – | – | 59.5% | 56.6% | 59.7% |
| Cash from operations to profit | – | – | – | – | – | – | 19.0% | 126.0% |
| Effective tax rate | 10.9% | 7.0% | 8.5% | – | – | 53.7% | 16.0% | 14.1% |
| +127.10% |
| −8.67% |
| Procter & Gamble Health | ₹5,595.50 | ₹9,288 cr | 24.5 | 57.7% | +17.70% | −6.69% |
|---|
| Aarti Pharmalabs | ₹986.75 | ₹8,948 cr | 35.4 | 11.2% | +45.90% | +16.93% |
|---|
| Healthcare Global Enterprises | ₹568.20 | ₹8,483 cr | 750.7 | 0.8% | +13.10% | −24.77% |
|---|
| Thyrocare Technologies | ₹509.65 | ₹8,112 cr | 56.3 | 26.1% | +25.10% | +15.46% |
|---|
Earnings Presentation for the quarter and half year ended September 30, 2026
Strides Delivers Strong Performance with Q2FY27 Revenue at ₹14,297m, Grew 17% YoYEx-US Markets Up 31% YoY; EBITDA Up 8% YoY to ₹2,509m, Crossing ₹2,500m in a Quarter for the First Time
The financial results for the period ended September 30, 2026.
Schedule of meet
Sustainability Report for FY26.
Completion of USFDA Inspection at the Company s Formulations Facility at Alathur
Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru
A copy Srutinizers report of Annual General Meeting held on August 14, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on August 14, 2026
Transcript of Earnings Call pertaining to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
Investor Presentation for Earnings call on Q1 FY 2027